Comparative Study of Two Tetanus Toxoid Vaccination Strategies: Cold Chain Versus Controlled Temperature Chain

Etude Comparative de Deux stratégies de Vaccination antitétanique en Situation réelle: Vaccin conservé en chaîne de Froid Versus en chaîne de température contrôlée.

The purpose of this study is to determine the effectiveness, safety and feasibility of a tetanus toxoid (TT) vaccination strategy relying on the maintenance of vaccines in a controlled temperature chain (CTC). The CTC is defined as the storage and transport of vaccines within a temperature range appropriate to the heat stability profile of TT vaccine. In this study vaccines are transported and stored in the cold chain up to district level. From district to beneficiary level vaccines are exposed to ambient temperatures during a limited period of time.

In an initial phase, the stability of 3 lots of TT vaccine kept in CTC is determined. For this, the potency, safety, pH and adsorption of vaccines maintained in CTC will be tested in the laboratory and compared to vaccines that have been maintained in cold chain. If all parameters (i.e. potency, safety, pH and adsorption) are above WHO specifications the strategy in CTC will be used.

Only if the laboratory results are adequate, villages will be assigned to one of the vaccination strategies. All women between 14 to 49 years of age in the selected villages who fulfill the inclusion criteria will be invited to participate.

In order to determine the baseline anti-tetanus protection, TT vaccination history will be collected from all participants using a standardized questionnaire. Women who have already received at least 2 doses of TT vaccine will be excluded from the study. Moreover, blood will be collected from all participants to later verify in laboratory the baseline protection.

A first dose of TT vaccine will be given according to the assigned strategy (CTC or cold chain). Four weeks after the 1st vaccination, a second TT vaccine will be given using the same strategy employed for the first dose. Finally, four weeks after the second dose, a blood sample will be collected from all participants who received two doses of vaccine. The serological responses will be compared in the group that received two doses of TT vaccine maintained in cold chain ant the group that received two doses of vaccine maintained in CTC.

Study Overview

• Status: Completed
• Conditions: Tetanus; Tetanus Vaccine
• Intervention / Treatment: Biological: Tetanus toxoid vaccine

• Study Type: Interventional
• Enrollment (Actual): 2129
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Chad
  • Moïssala, Chad
    • Moïssala health district

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years to 49 years (ADULT, CHILD)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Women aged between 14 to 49 years of age
• Living in the district of Moïssala, Chad
• Have no proof of previous vaccination or previous vaccination is not greater than 1 dose of vaccine
• Previous dose received more than 1 month before
• Consented to be included in the study

Exclusion Criteria:

• Allergic reaction to previous tetanus vaccination
• Severe febrile illness
• Have received a tetanus vaccine within the previous month
• Refuses vaccination or does not consent
• Nomadic population travelling before the end of the study
• Pregnant women due to deliver within 2 weeks

Study Plan

How is the study designed?

Design Details

• Primary Purpose: PREVENTION
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: SINGLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Cold chain; Group vaccinated with tetanus toxoid vaccine kept in cold chain	Biological: Tetanus toxoid vaccine; Two doses of tetanus toxoid vaccine separated at least 4 weeks. One arm receives the vaccine kept in cold chain and the other arm receives the vaccine kept in CTC
Experimental: CTC; Group vaccinated with tetanus toxoid vaccine kept in controlled temperature chain	Biological: Tetanus toxoid vaccine; Two doses of tetanus toxoid vaccine separated at least 4 weeks. One arm receives the vaccine kept in cold chain and the other arm receives the vaccine kept in CTC

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Protective level of anti-tetanus antibodies	The proportion of women who achieve a protective level of anti-tetanus antibodies after 2 doses of vaccine kept in CTC is not lower to the proportion of women who achieve a protective level of anti-tetanus antibodies after 2 doses of vaccine kept in cold chain.	4 weeks after second dose of vaccine

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Vaccine stability	Verify the stability of the vaccine (potency, safety, pH and adsorption) after exposure to ambient temperatures	30 days after exposure to ambient temperatures
Antibody levels	Evaluate the percentage increase in antibody levels in women who have received 2 doses of vaccine maintained in CTC and in women who have received 2 doses of vaccine maintained in cold chain	4 weeks after second dose of vaccine
Adverse events	Compare the adverse events in the group vaccinated with the vaccine kept in CTC and the group vaccinated with the vaccine kept in cold chain.	30 min and 7 days after vaccination

Collaborators and Investigators

• Sponsor: Epicentre
• Investigators: Principal Investigator: Aitana Juan Giner, MSc, Epicentre

Study record dates

Study Major Dates

• Study Start: November 1, 2012
• Primary Completion (Actual): March 1, 2013
• Study Completion (Actual): March 1, 2013

Study Registration Dates

• First Submitted: March 19, 2012
• First Submitted That Met QC Criteria: March 19, 2012
• First Posted (Estimate): March 21, 2012

Study Record Updates

• Last Update Posted (Estimate): May 3, 2013
• Last Update Submitted That Met QC Criteria: May 1, 2013
• Last Verified: February 1, 2013

More Information

Terms related to this study

• Keywords: vaccination; prevention of mother to child transmission; controlled temperature chain; outside the cold chain
• Additional Relevant MeSH Terms: Metabolic Diseases; Nervous System Diseases; Infections; Neurologic Manifestations; Bacterial Infections; Bacterial Infections and Mycoses; Gram-Positive Bacterial Infections; Neuromuscular Manifestations; Clostridium Infections; Hypocalcemia; Calcium Metabolism Disorders; Tetanus; Tetany
• Other Study ID Numbers: Epicentre/CTC-TT/2012